Complete all fields to establish unique identification of the affected shipment. This information is critical for regulatory traceability and audit trails.
Clinical Trial Site Number
Clinical Trial Site Name
Trial Site Full Address
Study Protocol Number
Clinical Trial Phase
Phase I
Phase II
Phase III
Phase IV
Bioequivalence
First-in-Human
Expanded Access
Study Sponsor Name
CRO/Monitor Contact Email
Investigational Product Batch/Lot Number
Drug Product Name/INN
Dosage Form
Lyophilized Powder
Solution for Injection
Tablet
Capsule
Oral Suspension
Topical Cream
Inhalation Powder
Other
Strength/Concentration
Shipment Tracking/AWB Number
Carrier/Logistics Provider
Shipment Receipt Date & Time
Total Number of Packages in Shipment
Number of Affected Packages
Was a temperature excursion detected during transit or upon receipt?
Number of Distinct Temperature Excursions Recorded
Detailed Temperature Excursion Log
Excursion Start Date/Time | Excursion End Date/Time | Minimum Recorded Temperature (°C) | Maximum Recorded Temperature (°C) | Specified Storage Range Min (°C) | Specified Storage Range Max (°C) | Duration Above/Below Threshold (minutes) | Temperature Monitoring Device ID | Device Data Successfully Downloaded? | |
|---|---|---|---|---|---|---|---|---|---|
6/15/2025, 2:30 PM | 6/15/2025, 4:45 PM | 8.5 | 12 | 2 | 8 | 135 | TEMP-DEVICE-789 | Yes | |
Temperature Excursion Severity Classification
Critical: Product integrity compromised
Major: Potential impact, requires investigation
Minor: Within acceptable tolerance limits
Unknown: Insufficient data for assessment
Select all temperature monitoring devices used in this shipment
Data logger (digital)
Chemical indicator (Freeze/Thaw)
Chemical indicator (Heat)
Electronic shipping indicator (ESI)
Real-time monitoring system (IoT)
None visible
Device missing or damaged
Was the temperature monitoring device calibrated within the last 12 months?
Upload temperature data logger graph/image files (PDF, JPG, PNG)
Detailed Assessment of Potential Impact on Product Quality & Efficacy
I confirm that temperature data has been reviewed by the site pharmacist or qualified designee
Was any packaging damage observed upon receipt?
Select all types of packaging damage or anomalies detected
Crushed outer carton
Torn or punctured packaging
Water damage or moisture intrusion
Compromised tamper-evident seal
Missing security seal
Incorrect or missing label
Dosage count discrepancy
Broken vials/ampules inside
Visible product contamination
No damage observed
Upload high-resolution photographs of all damaged packaging (multiple angles)
Was the shipment immediately quarantined upon detection of issues?
Physical Quarantine Location (room/area identifier)
Quarantine Secured By (name of personnel)
Quarantine Initiated Date & Time
Is the quarantine area temperature-monitored and within specified range?
Chain of Custody Documentation - Personnel Who Handled Shipment from Receipt to Quarantine
Were there any breaks in documented chain of custody?
I confirm that quarantined product is physically segregated and clearly labeled with QUARANTINE - DO NOT USE status
Is immediate replacement of quarantined investigational product required to maintain trial continuity?
Total Quantity of Replacement Product Required (units)
Estimated Replacement Product Value
Replacement Urgency Level
Emergency (dispatch within 24 hours)
Urgent (dispatch within 48 hours)
Standard (dispatch within 5 business days)
On Hold (awaiting investigation completion)
Requested Dispatch Date for Replacement Product
Preferred Courier/Logistics Provider for Replacement
Special Handling Requirements for Replacement Shipment
Enhanced temperature monitoring (real-time)
Double packaging (primary + secondary)
GPS tracking required
Adult signature mandatory
Weekend/Holiday delivery authorized
Dry ice replenishment en route
No special requirements
Is alternative batch/lot available for immediate dispatch?
Replacement Product Batch/Lot Number (if identified)
Has the patient/subject been notified of potential treatment delay?
Cost Center/Account Number for Replacement Shipment
Additional Risk Mitigation Measures for Replacement Shipment
This section requires dual authorization from both the Principal Investigator and Quality Assurance Director before any disposition decision is executed. Both parties must independently review all supporting documentation from Sections 1-4.
Principal Investigator Full Name
Principal Investigator License/Registration Number
Principal Investigator: Have you reviewed the complete quarantine documentation package?
Principal Investigator Assessment of Impact on Patient Safety & Data Integrity
Principal Investigator Recommended Disposition
Release for patient use (no quality impact)
Conditional release with protocol deviation documentation
Reject and destroy (product compromised)
Place on extended quarantine pending sponsor consultation
Await additional stability data
Quality Assurance Director Full Name
Quality Assurance Director Certification Number
QA Director: Have you verified that all regulatory requirements have been addressed?
QA Director Independent Assessment of GMP/GLP Compliance Status
QA Director Final Disposition Decision
Approve PI recommendation
Override PI - Release product
Override PI - Reject product
Escalate to Sponsor Quality Unit
Initiate Formal Deviation Investigation
Joint Justification for Final Disposition Decision
Principal Investigator Electronic Signature
Principal Investigator Sign-Off Timestamp
Quality Assurance Director Electronic Signature
Quality Assurance Director Sign-Off Timestamp
Both parties confirm that this decision has been made independently and without conflict of interest
Additional Comments or Escalation Notes